文献速递浆细胞疾病

不同年龄骨髓瘤患者预后因素的相对重要性:Myeloma XI 试验 3894 例结果

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
PubMed 文献 · Leukemia · 2019-10-14

分子事件对年轻患者预后影响更大,而体能状态在所有年龄组均重要,提示身体虚弱可能比年龄本身更能预测结局。

要点

  • 分子风险对年轻患者预后影响更大,在老年患者中相对贡献减弱。
  • 体能状态在所有年龄组均与预后相关,身体虚弱可能比年龄本身更重要。

核心结论

  • 不同年龄组中驱动骨髓瘤患者结局的因素存在显著差异,设计个体化治疗策略时应考虑年龄相关的预后因素权重变化。

研究设计与样本

  • 基于 Myeloma XI 大型临床试验中 3894 例全年龄段统一治疗的骨髓瘤患者数据进行分析。

主要发现

  • 肾功能随年龄增长而恶化,t(4;14) 和 del(17p) 频率随年龄增长而降低,gain(1q) 频率随年龄增长而升高。
  • 体能状态、国际分期评分和分子风险对 PFS 和 OS 的相对贡献因年龄组而异。
  • 分子事件对年轻患者结局影响更大,在老年患者中相对贡献减弱。
  • 体能状态在所有年龄组均对患者结局重要,提示身体虚弱可能比年龄本身更能预测结局。

临床怎么用

  • 在骨髓瘤患者预后评估和治疗分层中,应结合年龄考虑分子风险和体能状态的相对权重,尤其关注老年患者的体能状态而非仅年龄。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with patient age has not previously been investigated comprehensively. We analyzed data from 3894 patients of all ages uniformly treated in a large clinical trial of myeloma patients, Myeloma XI. Even with novel therapeutic approaches progression-free survival (PFS) and overall survival (OS) are affected by age with a stepwise reduction in PFS and OS with each decade increase. Renal function deteriorated with increasing age whilst the frequency of t(4;14) and del(17p) decreased and gain(1q) increased. The relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival varied by age group. Molecular events have a larger effect on outcome in younger patients with their relative contribution diminishing in the elderly. Performance status is important for patient outcome at all ages suggesting that physical frailty may be a more important predictor of outcome than age itself. Significant differences in the factors driving patient outcomes at different ages are important to consider as we design disease segmentation strategies to deliver personalized treatment approaches.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2019. PMID: 31611625. doi:10.1038/s41375-019-0595-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。